Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01475786 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
A Phase 2 study, sponsored by Helixmith Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT01475786 is a Phase 2 study that has completed, run by Helixmith Co.. The registered enrollment target is 104 participants.
The verdict
NCT01475786, a Phase 2 study, has completed, sponsored by Helixmith Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Engensis (VM202) is safe and effective in treating painful diabetic neuropathy.
Interventions
- BIOLOGICAL Low Dose: 16 mg Engensis (VM202)
- BIOLOGICAL High Dose: 32 mg Engensis (VM202)
- OTHER Control- Placebo (normal saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01475786
The ClinicalTrials.gov registry entry for NCT01475786 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helixmith Co., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Low Dose: 16 mg Engensis (VM202) is the first listed.
NCT01475786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01475786 about?
NCT01475786 is a clinical study titled "Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy". The purpose of this study is to determine if Engensis (VM202) is safe and effective in treating painful diabetic neuropathy.
What is the current status of trial NCT01475786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2012-08. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01475786?
The interventions under investigation include: Low Dose: 16 mg Engensis (VM202) (BIOLOGICAL), High Dose: 32 mg Engensis (VM202) (BIOLOGICAL), Control- Placebo (normal saline) (OTHER).
Who is sponsoring clinical trial NCT01475786?
This trial is sponsored by Helixmith Co., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.